JFG
NRIX icon

Jefferies Financial Group’s Nurix Therapeutics NRIX Stock Holding History

Jefferies Financial Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-62,000
Closed -$619K – 1866
2023
Q2 		$619K Buy
+62,000
New +$632K 0.01% 1107

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Financial Group's NRIX Position: Q3 2023 in Review

Jefferies Financial Group sold out of Nurix Therapeutics (NRIX) in Q3 2023, closing a stake of 62,000 shares — an estimated $619K sold.

Jefferies Financial Group first reported a position in NRIX in Q2 2023 and held it in 1 quarter. The position peaked at $619K in Q2 2023. 128 funds tracked by Wall St. Rank hold NRIX as of Q3 2023.

  • Jefferies Financial Group reported no remaining Nurix Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Jefferies Financial Group sold 62,000 Nurix Therapeutics shares in Q3 2023, an estimated $619K.
  • Jefferies Financial Group first reported a position in Nurix Therapeutics in Q2 2023 and held it in 1 quarter.
  • Jefferies Financial Group's Nurix Therapeutics position peaked at $619K in Q2 2023.
  • 128 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2023.

Based on Jefferies Financial Group's 13F filing for Q3 2023, filed 14 Nov 2023.